Medgend Icon







discontinued


Apriso FDA Approved Drugs

APRISO [MesalamineC7H7NO3]
RX
-
375mg (oral capsule, extended release)
Valeant Pharms IntlOct 31, 2008
  • For the maintenance of remission of ulcerative colitis in subjects 18 years of age and older.
  • For the maintenance of remission of ulcerative colitis.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

ASACOL HD [MesalamineC7H7NO3]
RX
-
800mg (oral tablet, delayed release)
ApilMay 29, 2008
  • Treatment of ulcerative colitis.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

CANASA [MesalamineC7H7NO3]
RX
-
1gm (rectal suppository)
Forest Labs LlcNov 5, 2004
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

DELZICOL [MesalamineC7H7NO3]
RX
-
400mg (oral capsule, delayed release)
ApilFeb 1, 2013
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

LIALDA [MesalamineC7H7NO3]
RX
-
1.2gm (oral tablet, delayed release)
ShireJan 16, 2007
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

MESALAMINE [MesalamineC7H7NO3]
RX
-
1.2gm (oral tablet, delayed release)
1gm (rectal suppository)
4gm/60ml (rectal enema)
Zydus Pharms Usa IncJun 5, 2017
Mylan Pharms IncNov 24, 2015
G And W Labs IncSep 30, 2004
Perrigo IsraelSep 17, 2004
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

PENTASA [MesalamineC7H7NO3]
RX
-
250mg (oral capsule, extended release)
500mg (oral capsule, extended release)
ShireMay 10, 1993
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

ROWASA [MesalamineC7H7NO3]
RX
-
4gm/60ml (rectal enema)
Mylan Speciality LpDec 24, 1987
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

SFROWASA [MesalamineC7H7NO3]
RX
-
4gm/60ml (rectal enema)
Mylan Speciality LpJun 20, 2008
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER [Conivaptan HydrochlorideC32H26N4O2ClH]
RX
-
20mg/100ml (0.2mg/ml) (iv (infusion) injectable)
Cumberland PharmsOct 8, 2008
  • Method of using antagonist of arginine vasopressin (ava) v1a and v2 receptors for intravenous treatment of patients with euvolemic hyponatremia.
  • Method of using antagonist of arginine vasopressin (ava) v1a and v2 receptors for intravenous treatment of patients with hypervolemic hyponatremia.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.